'Sweet spot' of CNS cell ther­a­py: Ke­nai emerges with $82M for Parkin­son's study

One of the first drugs that Jeff Jonas filed for ap­proval was a Parkin­son’s dis­ease treat­ment. Now, a lit­tle over a quar­ter-cen­tu­ry lat­er, af­ter ex­ec­u­tive roles at Shire and Sage Ther­a­peu­tics, he’s chair­ing a young start­up with $82 mil­lion to test whether an off-the-shelf cell ther­a­py can treat the CNS dis­or­der.

Ke­nai Ther­a­peu­tics emerged Thurs­day with the Se­ries A co-led by Alas­ka Per­ma­nent Fund Cor­po­ra­tion, The Col­umn Group and Cure Ven­tures, where Jonas is a part­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER